Accretion Pharmaceuticals manufactures and sells a wide range of generic medicines, including tablets, capsules, and liquids, for both its own brand and as a contract manufacturer for other pharmaceutical companies globally.
The company lacks a durable moat as it operates primarily as a price-taking CDMO in a fragmented market, evidenced by a sharp decline in EBITDA margins from 21% to 16% during a period of rapid volume expansion.
Management has prioritized aggressive capacity expansion and debt reduction using IPO proceeds, though the high negative cash conversion suggests significant capital is being tied up in working capital rather than generating immediate free cash flow.
The company's aggressive capacity expansion proved to be a value-destroying trap as the CDMO market commoditized further. While revenue grew, the lack of pricing power caused margins to continue their downward trajectory, and the massive working capital requirements—already visible in the negative cash conversion—eventually led to a liquidity crunch. The reputational fallout from the criminal litigation regarding labor practices alienated Tier-1 global pharmaceutical clients, leaving the company with underutilized facilities and a high fixed-cost base that eroded all shareholder equity.
RichFakir rates Accretion Pharmaceuticals Ltd's business quality as poor — 48/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Accretion Pharmaceuticals Ltd is trading about 92% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Accretion Pharmaceuticals Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Accretion Pharmaceuticals Ltd's fair value is about ₹96 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →